Christian Heidbreder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christian Heidbreder has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
Mark K. Greenwald
Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, United States
3 shared publicationsPaul J. Fudala
Indivior Plc, North Chesterfield, VA, United States of America
3 shared publicationsAzmi F. Nasser
From *Indivior Inc., Richmond, VA; †the Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI; and ‡Vince & Associates Clinical Research, Inc., Overland Park, KS
2 shared publicationsYongzhen Liu
Indivior Inc., Richmond, VA
2 shared publicationsAdel Kaplan
University of Florida, Gainsville, FL
1 shared publicationAlain Patat
Rennes, France
1 shared publication
Latest Publications
- Open Access
- 11 July 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1443304
Editorial: Discovery, development and implementation of improved options for treating opioid overdose in the synthetic opioid era
- 11 July 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1443304
Open AccessEditorial: Discovery, development and implementation of improved options for treating opioid overdose in the synthetic opioid era
- Open Access
- 6 March 2024
- Published by Elsevier in Neuroscience Applied
- Vol. 3
A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders
- 6 March 2024
- Published by Elsevier in Neuroscience Applied
- Vol. 3
Open AccessA novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders
- Open Access
- 10 January 2023
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 6, 100133
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
- 10 January 2023
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 6, 100133
Open AccessHistory of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
- Open Access
- 12 August 2022
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 4, 100090
The introduction of a novel formulation of buprenorphine into organized health systems
- 12 August 2022
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 4, 100090
Open AccessThe introduction of a novel formulation of buprenorphine into organized health systems
- Open Access
- 1 December 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 229 (Pt B) , 109057
Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS
- 1 December 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 229 (Pt B) , 109057
Open AccessAssessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS
- Open Access
- 1 January 2019
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 76, 93-103
Remission from chronic opioid use—Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics
- 1 January 2019
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 76, 93-103
Open AccessRemission from chronic opioid use—Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics
- Open Access
- 14 June 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (7) , 779-784
Issue Information
- 14 June 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (7) , 779-784
Open AccessIssue Information
- 1 February 2016
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 120, 142-152
Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry
- 1 February 2016
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 120, 142-152
Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry
- 1 February 2016
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 36 (1) , 18-26
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder
A major goal for the treatment of opioid use disorder is to reduce or eliminate the use of illicit opioids. Buprenorphine, a μ-opioid receptor partial agonist and kappa opioid receptor antagonist, is now being developed as a monthly, sustained-release formulation (RBP-6000). The objective of this study was to demonstrate that RBP-6000 blocks the subjective effects and reinforcing efficacy of the μ-opioid receptor agonist hydromorphone (intramuscularly administered) in subjects with moderate or severe opioid use disorder. Subjects were first inducted and dose stabilized on sublingual buprenorphine/naloxone (8–24 mg daily; dose expressed as the buprenorphine component), then received two subcutaneous injections of RBP-6000 (300 mg) on Day 1 and Day 29. Hydromorphone challenges (6 mg, 18 mg or placebo administered in randomized order) occurred on 3 consecutive days of each study week before and after receiving RBP-6000. Subjects reported their responses to each challenge on various 100-mm Visual Analogue Scales (VAS). Subjects also completed a choice task to assess the reinforcing efficacy of each hydromorphone dose relative to money. At baseline, mean “drug liking” VAS scores for hydromorphone 18 mg and 6 mg versus placebo were 61 mm (95% confidence interval, 52.3–68.9) and 45 mm (95% confidence interval, 37.2–53.6), respectively. After 300 mg RBP-6000 was administered, mean VAS score differences from placebo were less than 10 mm through week 12. The reinforcing efficacy of hydromorphone decreased in a parallel manner. This study demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder.
- 1 February 2016
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 36 (1) , 18-26
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder
A major goal for the treatment of opioid use disorder is to reduce or eliminate the use of illicit opioids. Buprenorphine, a μ-opioid receptor partial agonist and kappa opioid receptor antagonist, is now being developed as a monthly, sustained-release formulation (RBP-6000). The objective of this study was to demonstrate that RBP-6000 blocks the subjective effects and reinforcing efficacy of the μ-opioid receptor agonist hydromorphone (intramuscularly administered) in subjects with moderate or severe opioid use disorder. Subjects were first inducted and dose stabilized on sublingual buprenorphine/naloxone (8–24 mg daily; dose expressed as the buprenorphine component), then received two subcutaneous injections of RBP-6000 (300 mg) on Day 1 and Day 29. Hydromorphone challenges (6 mg, 18 mg or placebo administered in randomized order) occurred on 3 consecutive days of each study week before and after receiving RBP-6000. Subjects reported their responses to each challenge on various 100-mm Visual Analogue Scales (VAS). Subjects also completed a choice task to assess the reinforcing efficacy of each hydromorphone dose relative to money. At baseline, mean “drug liking” VAS scores for hydromorphone 18 mg and 6 mg versus placebo were 61 mm (95% confidence interval, 52.3–68.9) and 45 mm (95% confidence interval, 37.2–53.6), respectively. After 300 mg RBP-6000 was administered, mean VAS score differences from placebo were less than 10 mm through week 12. The reinforcing efficacy of hydromorphone decreased in a parallel manner. This study demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder.
- Open Access
The acute administration of the selective dopamine D3receptor antagonist SB‐277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats
We examined the effect of SB‐277011A, a selective D3receptor antagonist, on the conditioned place aversion (CPA) response associated with naloxone‐induced withdrawal from acute morphine administration in male Sprague‐Dawley rats. Morphine (5.6 mg/kg i.p.) was given, followed 4 hrs later by naloxone (0.3 mg/kg i.p.) and prior to placing the animals in one specific chamber of the test apparatus. All animals were subjected to 2 of these trials. A significant CPA occurred in animals that received an i.p. injection of vehicle 30 minutes prior to the measurement of chamber preference. The pretreatment of animals (30 minutes prior to testing) with 3 mg/kg i.p. of SB‐277011A did not significantly alter the CPA compared to animals treated with vehicle (1 ml/kg i.p. of deionized distilled water). In contrast, the acute pretreatment of animals with 6, 12 or 24 mg/kg i.p. of SB‐277011A significantly decreased the CPA compared to vehicle‐treated animals. In fact, the 12 and 24 mg/kg doses of SB‐277011A significantly increased the time spent in the chamber where animals were paired with morphine and naloxone. These results suggest that the selective antagonism of D3receptors attenuates the CPA produced by a model of naloxone‐induced withdrawal from acute morphine dependence. Synapse, 2012.
Open AccessThe acute administration of the selective dopamine D3receptor antagonist SB‐277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats
We examined the effect of SB‐277011A, a selective D3receptor antagonist, on the conditioned place aversion (CPA) response associated with naloxone‐induced withdrawal from acute morphine administration in male Sprague‐Dawley rats. Morphine (5.6 mg/kg i.p.) was given, followed 4 hrs later by naloxone (0.3 mg/kg i.p.) and prior to placing the animals in one specific chamber of the test apparatus. All animals were subjected to 2 of these trials. A significant CPA occurred in animals that received an i.p. injection of vehicle 30 minutes prior to the measurement of chamber preference. The pretreatment of animals (30 minutes prior to testing) with 3 mg/kg i.p. of SB‐277011A did not significantly alter the CPA compared to animals treated with vehicle (1 ml/kg i.p. of deionized distilled water). In contrast, the acute pretreatment of animals with 6, 12 or 24 mg/kg i.p. of SB‐277011A significantly decreased the CPA compared to vehicle‐treated animals. In fact, the 12 and 24 mg/kg doses of SB‐277011A significantly increased the time spent in the chamber where animals were paired with morphine and naloxone. These results suggest that the selective antagonism of D3receptors attenuates the CPA produced by a model of naloxone‐induced withdrawal from acute morphine dependence. Synapse, 2012.